MEDP vs RVTY
MEDP: Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development. RVTY: Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic applications across life sciences and diagnostics markets.
Side-by-side fundamentals
| Metric | MEDP | RVTY | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $605.82 | $113.17 | |
| Market cap as of 2026-07-24 | $17.4B | $12.5B | |
| P/E as of 2026-07-24 | 37.69 | 52.02 | MEDP lower |
| PEG as of 2026-07-24 | 2.71 | 5.11 | MEDP lower |
| Net margin as of 2026-07-24 | +17.2% | +8.3% | MEDP higher |
| Gross margin as of 2026-07-24 | +29.1% | +54.3% | RVTY higher |
| Operating margin as of 2026-07-24 | +21.0% | +12.4% | MEDP higher |
| ROE as of 2026-07-24 | +120.9% | +3.3% | MEDP higher |
| ROA as of 2026-07-24 | +24.8% | +2.0% | MEDP higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.45 | MEDP lower |
| Revenue growth (YoY) as of 2026-07-24 | +24.2% | +4.8% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +20.1% | -9.3% | MEDP higher |
| Dividend yield as of 2026-07-24 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-24 | 1.13 | 1.07 | |
| 1-year return as of 2026-07-23 close | +38.5% | +13.8% | MEDP higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.